Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422417 | 0.79 | GRIN2D (0.36) | CDK2GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL20867779 | 0.74 | HRH4 (0.33) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL22367851 | 0.74 | L3MBTL1 (0.36) | CDK2ABL1KDRELANE | |
| SCHEMBL15650935 | 0.68 | NUDT1 (0.34) | KDM4EGRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL19456816 | 0.68 | LMNA (0.35) | CDK2 | |
| SCHEMBL22899901 | 0.68 | LCK (0.34) | — | |
| SCHEMBL25244990 | 0.68 | FNTB (0.37) | KDM4E | |
| SCHEMBL20600838 | 0.65 | CCNE1 (0.33) | CDK2GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL30326244 | 0.65 | CCNE1 (0.33) | CDK2GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL21062848 | 0.65 | AXL (0.44) | CDK2GRIN2DGRIN3BGRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118451077-A | Bicyclic therapeutic compounds and methods for treatment of cancer | 基因泰克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | CDK2 1472/4885ABL1 74/4885KDR 4349/4885 |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | CDK2 1472/4885ABL1 74/4885KDR 4349/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | CDK2 1472/4885ABL1 74/4885KDR 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.